“`html
On November 6, 2025, Shore Capital reiterated a Buy recommendation for AstraZeneca PLC – Depositary Receipt (NasdaqGS:AZN). The average one-year price target is projected at $91.56/share, representing an 8.25% increase from its latest closing price of $84.58/share, with forecasts ranging from $45.71 to $125.85.
Projected annual revenue for AstraZeneca is $52,474MM, reflecting a decrease of 9.73%. Institutional ownership saw an increase to 1,740 funds, marking a 1.99% rise. However, total shares owned by institutions decreased by 2.42% to 637,486K shares.
The put/call ratio stands at 0.60, indicating a bullish market outlook. Notable share movements include Price T Rowe Associates decreasing their holdings by 9.90% to 51,943K shares, while Primecap Management increased their holdings by 1.31% to 41,200K shares.
“`
